Finoriq research workspace
AbCellera Biologics Inc. (ABCL) Historical Metrics
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for. Review ABCL valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- Company
- AbCellera Biologics Inc. (ABCL)
- Ticker
- ABCL
- Market Cap
- $1.7B
- Latest Price
- $5.855
- Industry
- Biotech & Pharma
AbCellera Biologics Inc. (ABCL) Current Valuation Metrics
Static valuation preview for AbCellera Biologics Inc. (ABCL). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 26.8x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -6.8% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -7.2% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 2.26x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.